AOD-9604 research guide

AOD-9604 in Maykop — Fat Loss Peptide Research Guide

AOD-9604 research guide for Maykop. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.

Skip to Sourcing Guide Order AOD-9604 →

Research-Grade AOD-9604 for Maykop Investigators

For anyone in Maykop looking to source AOD-9604, the first thing to know is that this compound moves through online research channels. This matters because AOD-9604 quality varies dramatically across the market — from analytically confirmed high-purity product to products with serious contamination — and the vendor is the entire quality system. Separating quality AOD-9604 from the rest of the market depends on three things: an HPLC chromatogram confirming ≥98% purity, mass spec data confirming the correct molecular weight, and a batch-specific endotoxin panel. Use this guide to verify vendor quality systematically — the framework here are universal across all research contexts.

Understanding AOD-9604 — Biology & Evidence

CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: AOD-9604 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Maykop comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.

AOD-9604 Purchasing Guide

Before assessing any particular supplier, build a clear picture of what a proper COA looks like — so you can tell whether a COA is complete and credible. A COA for AOD-9604 should include: HPLC purity percentage with the underlying chromatogram, mass spectrometry data establishing the correct molecular weight, endotoxin test results, and a residual solvent panel — all specific to the lot you receive. Red flags in AOD-9604 vendor evaluation: prices more than 30-40% below standard market rates, no information about manufacturing source, no community presence, and COAs that lack endotoxin data. For Maykop researchers making a first AOD-9604 purchase: work through this evaluation framework first, start with a modest quantity, and check that batch numbers on your vial match the COA before use.

Order AOD-9604 — ships to Maykop
COA-verified · International tracking · Research grade
Order Now →

AOD-9604 Research Safety Guide

Research compound status for AOD-9604 means the safety evidence is drawn from animal studies, in-vitro work, and limited human observations — rather than the large-scale clinical data that informs approved drug safety. Storage requirements for AOD-9604: lyophilised powder at −20°C, reconstituted solution stored refrigerated at 2-8°C and used within 30 days; reconstitute only with bacteriostatic water. Bacterial endotoxin contamination is the greatest safety hazard associated with research-grade peptides — verify endotoxin testing is documented in your batch COA before any injectable research application. Researchers combining AOD-9604 with other compounds should check the research literature for any reported interactions before running stacked compound experiments.

Frequently Asked Questions

What is the clinical trial history of AOD-9604?

AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.

How does AOD-9604 differ from growth hormone?

AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.

What is AOD-9604?

AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.

Order AOD-9604 today
COA-verified · International shipping available
Order Now →